Kwangdong Pharmaceutical Appoints Executive Director Ki-ryong Bae as Head of Pharmaceutical Research and Development Division

Kwangdong Pharmaceutical announced on the 9th that it has made a new appointment, naming Executive Director Bae Gi-ryong as Head of the Pharmaceutical Research and Development Division as of the 1st, to strengthen its research and development (R&D) capabilities.

Baek Gi-ryong, Head of Pharmaceutical Research and Development at Kwangdong Pharmaceutical. [Photo by Kwangdong Pharmaceutical]

With this appointment, Head Bae Gi-ryong will oversee the Pharmaceutical Research and Development Division and concurrently serve as the Head of the Pharmaceutical Business Development Division.

Head Bae graduated from the College of Pharmacy and Graduate School at Chung-Ang University. He subsequently worked at Daewoong Pharmaceutical, Handok Pharmaceuticals, GlaxoSmithKline (GSK) Korea, GSK Asia Pacific & Japan, and T&R Biofab.

After joining Kwangdong Pharmaceutical in 2017, he successfully led the New Business Task Force (TF), conducting various new business initiatives encompassing pharmaceuticals and health functional foods, including investments in domestic and international bio ventures. In 2020, he served as Head of the Pharmaceutical Business Strategy Division, achieving results such as establishing partnerships with global pharmaceutical companies to introduce products targeting unmet medical needs.

Recently, Kwangdong Pharmaceutical evaluated that he contributed to discovering new growth engines by stably managing the organization while undertaking challenging tasks, including proactively leading the business alliance agreement with Moderna, a leading biotech company in the messenger ribonucleic acid (mRNA) therapeutics and vaccine field.

This content was produced with the assistance of AI translation services.